Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption of Apixaban Sprinkle Capsules vs Tablets in Healthy Volunteers
NCT03509883Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apixaban in Atrial fibrillation (AFib), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration and 1 more. Started Apr 2018; status: completed.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT03509883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03509883.